Posts Tagged: COVID-19
Waiving IP Rights During Times of COVID: A ‘False Good Idea’
Over the course of four months, close to 850 million doses of COVID-19 vaccines have been administered in over 100 countries. To the extent the unprecedented pace of research, …
Countries Like the Philippines are Unable to Utilize IP Flexibilities to Fight COVID-19
The Philippines has so far relied on donations and direct purchase to obtain vaccines to address the pandemic. As of March 2021, the Philippines received 2 million Sinovac doses …
The mRNA IP and Competitive Landscape Through One Year of the COVID-19 Pandemic – Part I
Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the United States Food & Drug Administration (FDA) …
GIPC Event Underscores Scale of Dangerous COVID-Related Fakes During Pandemic
The U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC) held a webinar on Tuesday, April 6, as part of its Innovation Ecosystem series, titled “Worth …
Three Ways to Future-Proof Your IP Portfolio
The COVID-19 pandemic has caused a dramatic shift in how IP professionals manage their patent and trademark portfolios. Fortunately, many IP law firms and corporate IP departments …
Calls for Compulsory Licensing and IP Waivers of COVID-19 Vaccines Ignore Technical Complexities
Though it is not over, it seems that the end of the Covid-19 pandemic may be in sight. A select group of countries has managed to bring …
Why Innovation Would Survive a COVID-19 TRIPS Waiver
Intellectual property protection has played an important role in this pandemic. As some have pointed out, without legal protection for innovative ideas, there may not have been …
IP to Beat TB: How Efforts to Curb Tuberculosis Are Being Fueled by a Collaborative IP Ecosystem
One would think it was ripped from today’s headlines: a deadly respiratory disease sweeps across the world—killing one person every 22 seconds. But this disease is …
Who Deserves Recognition This Awards Season? A Robust, Resilient Creative Industry
After a year of cancellations and postponements, awards season is here. The competition for the best in film, TV, and music is fierce: There are underdogs, there …
As America Falls Off Global Innovation Map, an IP-Friendly USPTO Pick is More Crucial than Ever
As is customary, President Joseph R. Biden has spent much of his first month in office building out his administration’s Cabinet. His nominations for Secretary of …
Gutting Patents Won’t Speed the COVID-19 Vaccine Rollout
India and South Africa recently urged the World Trade Organization to suspend intellectual property protections for COVID-19 vaccines and treatments. The claim is that this would allow …
Pfizer Rejects Accusations it Infringed COVID-19 Vaccine Assay Technology
Pfizer and BioNTech have hit back at Allele Biotechnology and Pharmaceuticals, Inc.’s October 2020 complaint accusing the COVID-19 vaccine manufacturers of infringing Allele’s U.S. patent …
The Biden Administration is at an Innovation Crossroad
The new Presidential Administration has hardly settled in before being confronted with a stark choice: will they continue policies that foster public/private sector R&D partnerships …
Should the Biden Administration Look to Pharma for New USPTO Director?
The United States is not even two weeks into the administration of President Joe Biden and it’s likely that the administration’s selection for Director of …
New Year, New Models: How the Pandemic May Forever Change Practice at the USPTO
Last year brought unprecedented changes as to how the United States Patent and Trademark Office (USPTO) conducts business. Prior to the pandemic, the USPTO was already a …
